Lipanthyl S

Fenofibrate, the active ingredient in Lipanthyl S, is a fibrate presented as an oral tablet for oral administration. It is indicated for the management of hypertriglyceridemia, mixed dyslipidemia, and as an adjunct to statin therapy in primary hypercholesterolemia, helping to lower elevated triglyceride levels and improve overall lipid profiles in adult patients.

GNH USA supplies Lipanthyl S as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics across global markets while adhering to stringent quality standards and regulatory requirements.

Fenofibrate is used to treat disorders of lipid metabolism, particularly conditions characterized by elevated triglyceride levels. - Hypertriglyceridemia: lowers serum triglyceride concentrations and reduces risk of pancreatitis. - Mixed dyslipidemia: decreases triglycerides, modestly raises HDL‑cholesterol and contributes to overall lipid profile improvement. - Primary hypercholesterolemia (adjunct): used with statins to further reduce LDL‑cholesterol and triglycerides in patients requiring additional lipid lowering.

Fenofibrate may be associated with a range of adverse reactions, which are categorized by frequency and severity. Common Side Effects: - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Headache: mild to moderate intensity. - Elevated liver enzymes: transient increases in ALT or AST. - Muscle pain: mild myalgia without weakness. Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown, especially when combined with statins. - Acute liver injury: jaundice or hepatitis-like presentation. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe allergic reactions: rash, angioedema or anaphylaxis.

When prescribing Fenofibrate, clinicians should observe several precautionary measures to ensure safe use. - Liver function monitoring: obtain baseline enzymes and repeat periodically. - Renal function assessment: evaluate creatinine clearance, especially in severe impairment. - Gallbladder disease: avoid use in patients with active biliary obstruction or gallstones. - Concomitant statin therapy: use the lowest effective statin dose and monitor for myopathy. - Pregnancy and lactation: prescribe only if potential benefit justifies potential risk to the fetus or infant. - Store at room temperature: keep in the original container, protect from moisture and light.

Fenofibrate can interact with several medicines; understanding the interaction level guides clinical management. Major Interactions (Avoid): - Gemfibrozil: combined use markedly increases risk of myopathy and rhabdomyolysis. - High‑dose simvastatin: concurrent therapy raises the likelihood of severe muscle toxicity. - Warfarin: fenofibrate may potentiate anticoagulant effect, requiring INR monitoring. Moderate Interactions (Monitor Closely): - ACE inhibitors: monitor renal function and blood pressure for additive effects. - Oral contraceptives: may experience altered lipid levels, requiring periodic assessment.